ASP Isotopes, Inc. (ASPI)
NASDAQ:ASPI
Top Page
ASP Isotopes, Inc.
(NASDAQ:ASPI)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(31.09% Upside)
Action:ReiteratedDate:01/31/26
The score is held back primarily by weak financial quality (losses and high leverage) despite strong revenue growth. Technicals are neutral-to-slightly constructive near-term but weaker longer-term, and valuation remains challenging due to negative earnings and no dividend yield support. Earnings-call and corporate updates add some upside optionality via new facilities/contracts and recent strategic actions, but execution and guidance uncertainty keep the overall score below average.
Positive Factors
Revenue Growth & Gross Margin
Sustained high revenue growth coupled with a healthy gross margin signals durable end-market demand and initial pricing power for core isotope products. This supports scalable gross profits as production capacity ramps, enabling reinvestment in facilities and R&D to capture long-term market opportunities.
Negative Factors
Persistent Unprofitability
Material negative net and EBIT margins indicate core operations are not yet generating sustainable profits. Continued losses constrain self-funded growth, raise reliance on external financing, and heighten dilution or refinancing risk while the company scales capital-intensive enrichment facilities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Gross Margin
Sustained high revenue growth coupled with a healthy gross margin signals durable end-market demand and initial pricing power for core isotope products. This supports scalable gross profits as production capacity ramps, enabling reinvestment in facilities and R&D to capture long-term market opportunities.
Read all positive factors
ASP Isotopes, Inc. (ASPI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$630.55M
Dividend YieldN/A
Average Volume (3M)5.64M
Price to Earnings (P/E)―
Beta (1Y)1.98
Revenue Growth147.78%
EPS Growth-137.42%
CountryUS
Employees136
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,110,120
10 Day Avg. Volume6,314,928
30 Day Avg. Volume5,636,470
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)5.27
Price to Sales (P/S)60.85
P/FCF Ratio-8.99
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue51.33
Enterprise Value/Gross Profit223.21
Enterprise Value/Ebitda-4.05
Forecast
1Y Price Target
$12.00Price Target Upside124.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ASP Isotopes, Inc. Business Overview & Revenue Model
Company Description
ASP Isotopes Inc., a pre-commercial stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It develops Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-...
How the Company Makes Money
ASP Isotopes, Inc. generates revenue through multiple streams, including the sale of isotopes to hospitals and medical facilities for use in imaging and therapeutic procedures. The company also earns income from contracts with research institution...
ASP Isotopes, Inc. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
50
Neutral
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.38M | 4.14M | 433.03K | 0.00 | 0.00 |
| Gross Profit | 1.93M | 1.60M | 138.97K | -72.57K | -19.38K |
| EBITDA | -106.35M | -31.58M | -16.14M | -4.87M | -2.59M |
| Net Income | -105.56M | -32.33M | -16.29M | -4.79M | -2.61M |
Balance Sheet | |||||
| Total Assets | 225.89M | 94.35M | 30.19M | 12.50M | 7.14M |
| Cash, Cash Equivalents and Short-Term Investments | 113.94M | 61.89M | 7.91M | 2.39M | 2.95M |
| Total Debt | 113.66M | 37.75M | 2.14M | 822.20K | 926.60K |
| Total Liabilities | 129.29M | 43.18M | 11.36M | 2.68M | 1.14M |
| Stockholders Equity | 74.07M | 47.90M | 16.30M | 9.82M | 6.00M |
Cash Flow | |||||
| Free Cash Flow | -33.96M | -28.07M | -7.74M | -7.41M | -3.57M |
| Operating Cash Flow | -23.69M | -16.70M | -5.41M | -2.94M | -577.69K |
| Investing Cash Flow | -38.63M | -11.37M | -2.45M | -4.47M | -2.99M |
| Financing Cash Flow | 125.15M | 82.53M | 13.39M | 6.64M | 6.50M |
ASP Isotopes, Inc. Technical Analysis
Neutral
5.34
Price Trends
5.93
Negative
6.39
Negative
7.81
Negative
Market Momentum
-0.28
Positive
46.15
Neutral
42.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASPI, the sentiment is Neutral. The current price of 5.34 is above the 20-day moving average (MA) of 5.24, below the 50-day MA of 5.93, and below the 200-day MA of 7.81, indicating a bearish trend. The MACD of -0.28 indicates Positive momentum. The RSI at 46.15 is Neutral, neither overbought nor oversold. The STOCH value of 42.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ASPI.
ASP Isotopes, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.14B | 25.00 | -0.13% | ― | 12.49% | 95.48% | |
64 Neutral | $629.90M | 9.44 | 6.06% | 3.81% | -5.05% | 35.01% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
53 Neutral | $1.42B | -1.41 | -29.85% | 8.27% | -7.81% | -334.15% | |
52 Neutral | $751.80M | -0.94 | -99.73% | ― | -9.75% | -386.63% | |
49 Neutral | $630.55M | -16.54 | -187.23% | ― | 147.78% | -137.42% | |
47 Neutral | $1.53B | -49.30 | 128.17% | ― | -10.68% | 36.31% |
* Basic Materials Sector Average
ASPI
ASP Isotopes, Inc.
4.61
-0.12
-2.54%
BAK
Braskem SA
3.94
-0.14
-3.43%
LXU
Lsb Industries
16.88
9.88
141.14%
TROX
TRONOX
9.01
2.17
31.80%
RYAM
Rayonier Advanced Materials
10.81
5.04
87.35%
ASIX
AdvanSix
24.43
2.16
9.69%
ASP Isotopes, Inc. Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
ASP Isotopes Makes Strategic Equity Investment in Opeongo
Positive
Jan 30, 2026
On January 26, 2026, ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo, Inc. by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 preferred stock at $2.2952 per share, gaining a significant equity stake in a business d...
Business Operations and StrategyExecutive/Board ChangesM&A Transactions
ASP Isotopes strengthens leadership following Renergen acquisition closing
Positive
Jan 12, 2026
On January 7, 2026, ASP Isotopes announced new leadership appointments tied to the January 6, 2026 closing of its acquisition of Renergen Limited, naming Renergen CEO and co-founder Stefano Marani as President, Electronics and Space, and Renergen ...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A Transactions
ASP Isotopes Completes Renergen Acquisition and Integration
Positive
Jan 7, 2026
On January 6, 2026, ASP Isotopes Inc. completed its previously announced all-stock acquisition of South Africa-based Renergen Limited, a producer of liquefied helium and liquefied natural gas, via a court-approved scheme of arrangement under South...
Executive/Board ChangesShareholder Meetings
ASP Isotopes Reaffirms Board Leadership and Auditor Appointment
Positive
Dec 19, 2025
ASP Isotopes Inc. held its 2025 Annual Meeting of Stockholders on December 18, 2025, at which shareholders addressed director elections and the appointment of the company’s external auditor. At the meeting, stockholders re-elected two Class ...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsRegulatory Filings and Compliance
ASP Isotopes advances Renergen acquisition after compliance approval
Positive
Dec 18, 2025
On December 18, 2025, ASP Isotopes Inc. confirmed that South Africa’s Takeover Regulation Panel had issued a compliance certificate for its scheme of arrangement to acquire all issued ordinary shares of Renergen Limited, under which Renergen...
Executive/Board Changes
ASP Isotopes Announces CEO Role Change
Neutral
Dec 8, 2025
ASP Isotopes Inc. announced that effective January 19, 2026, Paul Mann, the founder and Executive Chairman, will resume his role as Chief Executive Officer while continuing as Executive Chairman. Robert Ainscow, who served as Interim CEO during Ma...
Business Operations and StrategyPrivate Placements and Financing
ASP Isotopes Announces $64.3M Convertible Note Agreement
Positive
Nov 14, 2025
On November 7, 2025, Quantum Leap Energy LLC, a subsidiary of ASP Isotopes Inc., announced a Convertible Note Purchase Agreement to issue and sell $64.3 million in convertible promissory notes to accredited investors. The proceeds will be used to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.